Future studies of imaging–pathology correlation using 18F-florzolotau in patients with FTD due to diverse tau pathologies, including Pick’s disease, CBD and PSP, will be required to validate the capability of this radioligand for detecting and differentiating various FTLD tauopathies in vivo. This evidence concerns the gene MAPT and tauopathy.